Eferox

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eferox

What is Eferox? A Foundational Overview

Property Description
Active ingredient Levothyroxine Sodium
Form Oral tablet (primary), capsule, solution
Pharmacological class Thyroid Hormone Replacement
General purpose Restoring and maintaining metabolic balance
Origin Synthetic L-thyroxine

What Type of Medicine is Eferox (Levothyroxine Sodium)?

Eferox is a prescription-only medication whose active component is Levothyroxine Sodium, a synthetic form of the critical thyroid hormone thyroxine (Tetraiodothyronine or T4). It belongs to the Thyroid Hormone Replacement class, acting as a direct substitute for the hormone normally produced by the thyroid gland. Levothyroxine is an established therapy used to address hormonal deficiency caused by an underactive thyroid gland. This means the medication acts by replacing the essential chemical messenger that the body is missing, a mechanism that is clinically recognized for its efficacy in restoring systemic function.

Composition, Form, and General Purpose

The composition of Eferox is a single-ingredient product, containing only Levothyroxine Sodium in a pharmaceutical base, and is primarily administered via the oral tablet form. This formulation is distinctive, offering a standard and stable means of delivery. The overriding general purpose of this therapy is to restore and maintain the overall metabolic balance in the body. The goal of Levothyroxine therapy is to consistently maintain the patient in a euthyroid state—a condition where thyroid hormone levels are normal. Achieving this stability helps support the normal function of all major organ systems, including the brain, heart, and liver, often used in scenarios requiring consistent long-term hormonal replacement.

Comparison: Synthetic vs. Natural Hormones

Eferox is defined by its precise structure as synthetic L-thyroxine. Unlike treatments using desiccated animal thyroid extract, which contains a combination of T4 and the more active T3 hormones, Levothyroxine Sodium offers pure T4. This standardized, single-molecule approach allows for highly consistent dosing, which is essential given that this class of medication has a narrow therapeutic index. This pure T4 replacement enables the body's natural systems to manage the conversion of T4 into T3 as required by cellular demand.

Regulatory References

  1. Levothyroxine - StatPearls - NCBI Bookshelf - NIH
  2. Levothyroxine: MedlinePlus Drug Information

What side effects are possible with Eferox?

Eferox: Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety statements for Eferox (venlafaxine), based strictly on governmental regulatory documents.


Adverse Reactions and Frequencies

Side effects are categorized based on their official frequency of occurrence in clinical trials:

Classification Examples of Reactions
Very Common (Affects 1 in 10 people or more) Nausea, dry mouth, dizziness, insomnia, somnolence, sweating, headache, constipation.
Common (Affects 1 to 10 in 100 people) Anxiety, nervousness, tremor, visual disturbance, hypertension (high blood pressure), tachycardia, vomiting, sexual dysfunction (e.g., abnormal ejaculation, decreased libido).

Serious reactions are listed under various System-Organ Classes, including the nervous system, vascular system, and metabolic system.


Clinically Significant and Serious Safety Concerns

The product label includes a Boxed Warning regarding the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults, requiring close monitoring, particularly during the initial weeks of treatment or following dose changes.

Serious Adverse Reactions documented in official labeling include:

  • Serotonin Syndrome: A potentially life-threatening condition, particularly when Eferox is used with other serotonergic medicines.
  • Cardiovascular Risks: Dose-related and sustained increases in blood pressure and heart rate have been observed, requiring regular monitoring.
  • Seizures and Angle-Closure Glaucoma (increased pressure in the eye).

Safety Restrictions and Special Populations

Eferox is strictly contraindicated for use in combination with a Monoamine Oxidase Inhibitor (MAOI), or within 14 days of discontinuing an MAOI, due to the high risk of Serotonin Syndrome.

  • Hepatic and Renal Impairment: Dose adjustments are required for patients with moderate to severe liver or kidney disease.
  • Discontinuation Syndrome: The medication must be tapered gradually under professional guidance upon cessation to avoid withdrawal reactions.

Overdose and Emergency Response

Overdose and when to seek help

The officially documented manifestations of overdosage with Eferox (Levothyroxine Sodium) are symptoms consistent with acute thyrotoxicosis (excess thyroid hormone). Regulatory sources emphasize that urgent medical attention must be sought immediately due to the potential for serious or life-threatening outcomes.

Documented Overdose Presentations

System Manifestations of Overdosage
Cardiovascular Tachycardia, palpitations, arrhythmias, heart failure, and myocardial infarction.
Central Nervous System Headache, nervousness, anxiety, irritability, insomnia, tremors, and rarely, seizures.
General/Metabolic Fatigue, weight loss, fever, heat intolerance, and excessive sweating.

Required Emergency Actions

Overdosage, particularly large doses, may lead to severe outcomes, including cardiac arrest. The risk is increased in elderly patients and individuals with underlying cardiovascular disease. Therefore, regulatory guidance mandates seeking immediate medical attention for suspected overdosage. Management is officially described as symptomatic and supportive treatment, including discontinuing the drug. No specific antidote is known, and close observation of the patient is required.

Therapeutic Uses of Eferox

What Eferox Treats: Main Uses and Benefits

Eferox is commonly used as a replacement therapy for all forms of hypothyroidism, including primary, secondary, and congenital deficiency. The medication is applied in addressing the systemic imbalance associated with the condition. This contributes to easing the overall symptom load and supports metabolic stability in situations where patients experience chronic deficiency, and is considered relevant for assisting with healthy development in pediatric patients.


The medication is applied in addressing symptoms related to metabolic slowdown. This domain is used for managing symptom clusters such as noticeable fatigue, general lethargy, chronic cold intolerance, and physical discomforts like persistent constipation and generalized muscle or joint aches. This use may be part of symptomatic management across conditions presenting with these systemic symptoms, and the therapeutic benefit contributes to improved comfort and assists with maintaining functional stability.

Beyond replacement, Eferox may be part of symptomatic management for thyroid cancer. It is also commonly used to help with reducing the size of, or preventing the growth of, an enlarged thyroid gland (goiter), providing supportive relief when symptoms interfere with routine activities.


Quick Fact: Relief for Chronic Fatigue

The medication plays a role in managing symptoms related to metabolic slowdown, assisting with reducing the burden of fatigue and lethargy, and contributing to supporting general well-being.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility to use Eferox (Levothyroxine Sodium) is strictly defined by regulatory authorities based on a patient's existing health status, independent of the hypothyroid condition being treated.

Who Must Not Use Eferox (Contraindications)

Eferox is absolutely contraindicated in several populations. These include patients with untreated thyrotoxicosis (excessive thyroid hormone levels) or those with uncorrected adrenal insufficiency, as starting treatment could trigger a life-threatening acute crisis. Use is also strictly forbidden in patients experiencing acute myocardial infarction, acute myocarditis, or acute pancarditis due to the increased metabolic demands the drug places on the heart. Furthermore, the medication must not be used in euthyroid individuals seeking treatment solely for obesity or weight loss.

Populations with Restricted or Conditional Use

Certain populations require special consideration and typically a lower starting dose. This applies to older adults (geriatric patients) and individuals with underlying cardiovascular disease (such as coronary artery disease), where cautious, slow dose titration is mandated to prevent cardiac events. For pregnant women, treatment is generally continued and often requires a dose increase. Use is also permitted during breastfeeding. Patients with diabetes mellitus or those with a history of epilepsy require careful monitoring during therapy.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Eferox (Levothyroxine Sodium) based on three primary mechanisms: altered absorption, modified metabolism/clearance, and pharmacodynamic potentiation.

Timing and Absorption-Based Interactions

Co-administration with agents that bind Levothyroxine in the gastrointestinal tract is documented to reduce its exposure by impairing absorption. To minimize this effect, administration of Eferox must be separated by at least four (4) hours from products containing Iron Salts, Calcium Salts, Aluminum-containing Antacids, and Cation Exchange Resins (e.g., Cholestyramine). Foods, including soy products and high-fiber meals, are also officially documented to decrease Levothyroxine absorption.

Pharmacodynamic and Metabolic Effects

Oral Anticoagulants (e.g., Warfarin) may have their effects potentiated by Levothyroxine, requiring close and frequent monitoring of INR/prothrombin time. Co-administration with Antidiabetic Agents (e.g., Insulin) may worsen glycemic control, potentially necessitating adjustment of the antidiabetic regimen. Furthermore, CYP3A4 inducers (e.g., Rifampin) are documented to increase Levothyroxine metabolism, which may result in increased Levothyroxine dosage requirements. Oral Estrogens are noted to increase plasma T4-binding globulin, also potentially requiring a dose increase.

Mechanism of Action

Prohormone Conversion and Nuclear Receptor Agonism

The mechanism of Eferox (Levothyroxine Sodium) is one of endocrine replacement, functioning as a synthetic prohormone to substitute for deficient levels of T4 across major organ systems. The drug's primary action relies on its uptake and subsequent enzymatic conversion into the active hormone T3 by the 5′-Deiodinase enzymes (DIO2) in target tissues. T3 then acts as a full agonist at the Thyroid Hormone Receptors ( THRalpha and THRbeta) within the cell nucleus, initiating the modulation of gene expression.

Genomic Regulation of Basal Metabolic Rate

This molecular interaction triggers a genomic cascade, where the T3- THR complex increases the transcription rate of genes responsible for key metabolic enzymes, such as Na^+/ K^+- ATPase. This effect systematically elevates the rate of cellular oxygen consumption and heat production, serving as the central mechanism for the regulation of the body's basal metabolic rate (BMR).

Systemic Feedback and Cardiovascular Modulation

The active hormone establishes a vital negative feedback loop on the pituitary gland, which suppresses the pathological release of TSH, modulating hormonal concentrations. The genomic action also increases beta-adrenergic receptor density in the heart, sensitizing the organ to catecholamines and modulating heart rate and contractility as a consequence of the systemic metabolic effect.

Dosage and Administration Information

How Eferox is Used: Official Administration Guidelines

Eferox (Levothyroxine Sodium) is administered according to a specific protocol to ensure consistent drug absorption and predictable response. The instructions are standardized to maintain therapeutic consistency and optimal metabolic balance.


Administration Scope

Instruction Entity Official Guideline
Route of Administration Primarily oral. The Intravenous (IV) route is reserved for specialized, acute scenarios, such as myxedema coma.
Dosing Schedule Administered as a single daily dose. The adult full replacement dose is typically around 1.6 mcg per kg of body weight per day. Dose adjustments are typically made in 12.5 mcg to 25 mcg increments.
Timing in Relation to Meals Must be taken on an empty stomach, specifically one-half to one hour before breakfast to ensure optimal absorption.
Special Procedural Conditions Dosing must be separated by at least 4 hours from drugs known to impair its absorption.

Procedural and Population-Specific Rules

Treatment for hypothyroidism is generally a lifelong commitment. Dose changes are made cautiously, with at least 4 to 6 weeks necessary between adjustments to allow the full therapeutic effect of the new dose to be reached.

Age-Group Administration Rules:

  • Older Adults (especially those with cardiac risk) are started on a lower dose, typically 12.5 mcg to 25 mcg per day.
  • Neonates (0–3 months) require the highest relative weight-based dose, ranging from 10 to 15 mcg per kg per day.

For infants unable to swallow, tablets may be crushed and suspended in a small amount of water for immediate use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Eferox (Levothyroxine Sodium)

Evidence for Use in Overt Thyroid Hormone Deficiency

Research has consistently observed Eferox in observational settings evaluating daily-life functioning as a synthetic replacement for the natural hormone T4 in cases of clear thyroid deficiency (overt hypothyroidism). The long-standing use of Levothyroxine is the foundation of the evidence, which is supported by decades of clinical experience and regulatory review. Studies monitored the role of the therapy in addressing systemic or functional imbalance in populations including adults, older adults, and pediatric patients with congenital deficiency.

The findings describe patterns observed in the studies where treatment reported patterns related to the normalization of key thyroid blood markers, such as Thyroid-Stimulating Hormone (TSH) and Free T4. Reports across decades of clinical experience describe patterns of symptom changes (e.g., in fatigue and cold intolerance) used in research exploring how symptoms change over time.

Evidence for Use in Subclinical Hypothyroidism

For subclinical hypothyroidism—where TSH is elevated but Free T4 is typically normal—the research is structured differently, primarily using short-term Randomized Controlled Trials (RCTs). These studies explored outcomes related to functional limitations and outcomes describing episodic or acute changes in symptoms like fatigue or quality of life. The study populations were typically adults who were often stratified based on the degree of TSH elevation.

Studies reported how symptoms evolved in the observed populations, but findings were mixed regarding changes in symptoms such as fatigue, mood, or cognitive function compared to an inactive substance (placebo). While the research consistently data show patterns related to the normalization of the elevated TSH level, research has explored whether this normalization translates into consistent changes in daily functioning or activity level, with findings that were mixed.

Evidence in Special Populations

Specific research has been conducted for particular patient groups, notably pediatric patients and pregnant women. For children with congenital hypothyroidism, the therapy was studied for maintaining normal thyroid levels. For pregnant women with subclinical hypothyroidism, RCTs research examined whether initiating treatment was observed in some studies to modify outcomes related to adverse obstetrical events. However, research focusing on long-term neurodevelopmental outcomes in children born to treated mothers was observed in some studies to be inconclusive.

Key Studies & References

  1. Levothyroxine: MedlinePlus Drug Information (Authoritative overview of established use)
  2. Thyroid Stimulating Hormone (TSH) Suppression - ThyCa (Referencing ATA/ETA Guidelines)
  3. Pregnancy and Neonatal Outcomes With Levothyroxine Treatment in Women With Subclinical Hypothyroidism Based on New Diagnostic Criteria: A Systematic Review and Meta-Analysis
  4. Levothyroxine for the Treatment of Subclinical Hypothyroidism and Cardiovascular Disease (Discusses mixed findings on CVD and symptoms in SCH)

Frequently Asked Questions (FAQ)

Common questions about Eferox (FAQ)

Q: What is the difference between Eferox and similar treatments like [SimilardrugA]?

Eferox is a synthetic form of the hormone T4 (thyroxine). It is a single-molecule replacement therapy that is chemically distinct from other thyroid treatments, such as those that contain a mixture of T4 and T3 (like desiccated thyroid extract). Official information indicates that this pure T4 replacement allows the body's natural systems to manage the conversion to T3.

Q: Is it normal to feel tired when first starting Eferox?

Official product information indicates that side effects affecting the central nervous system, such as somnolence (drowsiness), have been reported. For some users, feeling tired may be experienced when initiating treatment. Persistent or severe changes in energy level are typically reviewed by a healthcare provider.

Q: Does Eferox have the potential to cause weight changes (gain or loss)?

Weight loss and increased appetite are listed in official documents as adverse reactions primarily associated with therapeutic overdosage (receiving too much of the hormone). Furthermore, regulatory documents strictly state that Eferox is contraindicated for use solely for the purpose of weight reduction in individuals with normal thyroid function.

Q: Can Eferox cause changes in mood or anxiety levels?

Official documentation states that adverse reactions affecting the nervous system include feelings of anxiety, nervousness, irritability, and emotional lability. If significant changes in mood are experienced, guidance is generally sought from a prescribing physician.

Q: Does Eferox interact with common food items, such as grapefruit?

Yes, the official product label documents an interaction with grapefruit juice. Consuming grapefruit juice may delay the absorption of Eferox and reduce the total amount of the drug that enters the body. This potential effect on bioavailability may be a factor when determining dosage requirements.

Q: Does Eferox affect the effectiveness of birth control pills?

Oral Estrogens, a common component in certain birth control pills, can increase the need for the active ingredient in Eferox. This physiological change may require an increase in the prescribed Eferox dosage to maintain the appropriate hormone balance.

Q: Can people with a history of high blood pressure safely take Eferox?

Official regulatory documents state that individuals with underlying cardiovascular conditions, including hypertension (high blood pressure), should have therapy initiated cautiously at reduced dosages. Close monitoring of cardiovascular function is also mandated during treatment to ensure safety.

Q: What type of monitoring (e.g., blood tests) might be recommended while on Eferox?

The adequacy of treatment with Eferox is routinely determined through periodic monitoring. This typically involves blood tests that measure the levels of TSH (Thyroid-Stimulating Hormone) and/or Thyroxine (T4), alongside an assessment of the patient's clinical status.

Q: Why do some people report seeing no benefits from taking Eferox?

Official information indicates that the peak therapeutic effect of any given dosage may take 4 to 6 weeks to be fully realized. Inadequate response may also be related to taking the medication incorrectly, poor compliance, or interactions with certain foods or other drugs that impair absorption.

Q: What should be done if an allergic reaction to Eferox is suspected?

Hypersensitivity reactions to the inactive ingredients in Eferox have been reported, with symptoms that can include rash, hives, swelling, and fever. Official patient information indicates that if an allergic reaction is suspected, a healthcare provider is typically contacted immediately.

Q: Does the efficacy of Eferox vary based on patient demographics like age or sex?

The dosage of Eferox is highly individualized and is based on a number of patient-specific factors, including age, body weight, and cardiovascular status. Official guidelines mandate age-specific dosing (such as lower starting doses for older adults) to ensure a safe and effective treatment profile.

Q: What is the long-term safety profile of Eferox, according to studies?

Official documents warn that long-term overtreatment with the active ingredient in Eferox may lead to negative health consequences. These include a potential decrease in Bone Mineral Density and an increased risk of cardiac adverse events, such as atrial fibrillation, especially in elderly patients.

Q: How quickly does Eferox typically begin to have an effect?

The regulatory documents state that the peak therapeutic effect of any particular dose of Eferox may not be attained for 4 to 6 weeks. This duration is necessary to allow the medication to fully stabilize hormone levels in the body.

Q: If I miss taking Eferox for a day, does it affect the overall treatment outcome?

Due to the slow elimination rate of the active ingredient (T4) in Eferox, with an average half-life of 6 to 8 days, missing a single day's dose typically does not significantly affect the overall long-term treatment outcome. However, doubling up on subsequent doses to make up a missed dose is not the recommended procedure.

Q: Is Eferox classified as a controlled substance?

Eferox is a prescription medication but is not classified as a controlled substance under regulatory guidelines. The drug is listed with a DEA Schedule: None, indicating it is not associated with abuse potential.

Q: Can herbal supplements like St. John's Wort be taken concurrently with Eferox?

Evidence indicates that taking the herbal supplement St. John's wort alongside Eferox may decrease the overall effectiveness of the thyroid medication. If this supplement is used, the potential need for an adjustment to the Eferox dosage is generally reviewed by a healthcare professional.

Q: Is there ongoing research or clinical trials related to new uses for Eferox?

The official label for Eferox defines specific Indications (approved uses) and also includes Limitations of Use, which detail conditions for which the drug is specifically not indicated. This information stems from clinical research that defines the boundaries of the drug’s approved use.

Q: Is the medication Eferox known to be addictive or habit-forming?

Eferox is not classified as a controlled substance and is not considered to be an addictive or habit-forming medication. The primary safety restriction is its contraindication for use as a weight-loss drug due to potential toxicity.

Q: How long does Eferox stay in the system after the last dose?

The active ingredient in Eferox is eliminated slowly from the body. Regulatory documents report that the half-life—the time it takes for half of the drug to be eliminated—is approximately 6 to 8 days in individuals with normal thyroid function.

Q: Is there a generic version of Eferox available?

Yes, the active ingredient in Eferox is called Levothyroxine Sodium, which is the generic name for the medication. There are multiple FDA-approved generic and brand-name formulations of this drug available.

Q: Is Eferox known to affect appetite?

Increased appetite is listed in official documentation as an adverse reaction that is primarily associated with receiving an excessive amount of the medication (overdosage).

How should Eferox be stored and disposed of?

How to Store and Dispose of Eferox?

Eferox (Levothyroxine Sodium) must be stored under controlled conditions to maintain its stability, as defined in official regulatory labeling.

Storage Requirements

The medicine must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F). The product must be protected from light and moisture and kept in the original container.

Condition Requirement
Temperature 20 C to 25 C
Container Store in original container, protected from light and moisture
Child Safety Keep out of the sight and reach of children

Disposal Instructions

Unused or expired Eferox should be disposed of through a drug take-back program if one is available. If not, the medicine should be mixed with an undesirable substance, sealed in a bag or container, and discarded in the household trash, in accordance with governmental instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eferox found in:

A-Z Index: